A multicenter, randomised, parallel group, double-blind, placebo-controlled flexible dose study with an open-label extension to assess the efficacy and safety of Viagra (sildenafil citrate) in the treatment of men with erectile dysfunction (ED) and concomitant lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in the United States

Trial Profile

A multicenter, randomised, parallel group, double-blind, placebo-controlled flexible dose study with an open-label extension to assess the efficacy and safety of Viagra (sildenafil citrate) in the treatment of men with erectile dysfunction (ED) and concomitant lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in the United States

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2007

At a glance

  • Drugs Sildenafil (Primary)
  • Indications Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top